Maxime Liberelle holds an MSc in drug design from University of Lille (France), awarded in 2015. He obtained his PhD in structural biochemistry in 2019 on the characterization, structure–function relationships, and therapeutical targeting of oncogenic complex MUC4-ErbB2 under the supervision of Nicolas Lebègue at the University of Lille in the laboratory of Patricia Melnyk. After a 2-year postdoc position at the University of Louvain (UCLouvain, Belgium), with Raphaël Frédérick, he joined the University of Lille, where he is associate professor of biophysics and medicinal chemistry. His research focuses on the protein–protein interaction field, from characterization to targeting.